更新于：2024-12-09
Silodosin
赛洛多辛
更新于：2024-12-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
102
项与 赛洛多辛 相关的临床试验Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Silodosin Tablets 4 mg manufactured by SRIPRASIT PHARMA CO., LTD., relative to Urief Tablets 4 mg, in healthy Thai male volunteers under fed condition
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
481
项与 赛洛多辛 相关的文献（医药）2024-11-01Annales Pharmaceutiques Francaises
Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach
Article
作者: Kadioglu, Yucel ; Aydin, İsmail Cagri ; Erkayman, Beyzagul ; Senol, Onur ; Akman, Tugrul Cagri
BACKGROUND:
Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration.
MATERIALS AND METHODS:
The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41m/z values with significant differences between the drug-treated and control groups (p <0.01 and fold analysis≥1.5).
RESULTS:
According to multivariate data analysis, 17-β-estradiol, taurocholic acid, L-kynurenine, N-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5'-methylthioadenosine, L-methionine and S-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways.
CONCLUSIONS:
The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine.
2024-05-01Naunyn-Schmiedeberg's archives of pharmacology
Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens
Article
作者: Guimarães, Renan Arthur Bosio ; Fregonesi, Adriano ; De Nucci, Gilberto ; Antunes, Edson ; Oliveira, Denis Lima ; Britto-Júnior, José ; de Oliveira Stocco, Gabriel Augusto ; Lima, Antonio Tiago ; Salgado Uramoto, Edson Hiroshi ; Quirino Junior, Gilberto
6-Nitrodopamine (6-ND) is released from human vas deferens and plays a modulatory role in the male ejaculation. Therapeutical use of α1-adrenoceptor antagonists is associated with ejaculatory abnormalities. To evaluate the effect of α1-adrenoceptor antagonists on the contractions induced by 6-ND, dopamine, noradrenaline, and adrenaline in the human epididymal vas deferens (HEVD). HEVD strips were suspended in glass chambers containing heated and oxygenated Krebs-Henseleit's solution. Cumulative concentration-response curves to catecholamines (10 nM-300 μM) were constructed in HEVD strips pre-incubated (30 min) with doxazosin (0.1-1 nM), tamsulosin (1-10 nM), prazosin (10-100 nM) and/or silodosin (0.1-10 nM). The effects of these α1-adrenoceptor antagonists were also evaluated in the electric-field stimulation (EFS, 2-32 Hz)-induced contractions. Doxazosin (0.1 nM) caused significant reductions in 6-ND-induced HEVD contractions without affecting the contractions induced by dopamine, noradrenaline, and adrenaline. Similar results were observed with tamsulosin (1 nM) and prazosin (10 nM). At these concentrations, these α1-adrenoceptor antagonists largely reduced the EFS-induced contractions. Silodosin (1 nM) caused concentration-dependent rightward shifts of the concentration-response curves to 6-ND but had no effect on the contractions induced by dopamine and adrenaline. Silodosin (0.1 nM) only inhibited the contractions induced by noradrenaline. Silodosin at 1 nM, but not at 0.1 nM, caused significant reductions in the EFS-induced contractions. The results reinforce the concept that 6-ND plays a major role in the human vas deferens contractility and indicate that the ejaculation disorders caused by doxazosin, tamsulosin, prazosin and silodosin cause in man, may be due to inhibition of the contractions induced by 6-ND rather than by the classical catecholamines dopamine, noradrenaline, and adrenaline.
2024-03-01Annales pharmaceutiques francaises
Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture
Article
作者: Surekha, Ninama ; Mishra, Shweta ; Chauhan, Ashlesha
The study focuses to validate and develop a precise, simple and accurate stability indicating RP-HPLC method for estimation simultaneously of and silodosin and mirabegron in synthetic mixture. The chromatographic separation was achieved by using Shimpack Solar C18 column (250×4.5mm, 5μm) with acetonitrile: 5mM ammonium acetate in ratio of 90:10% v/v as a mobile phase at a constant flow rate of about 1.2mL/min. The development and validation were carried out at detection wavelength of 229nm. We developed a robust RP-HPLC method, validated for linearity, precision, accuracy, specificity, and system suitability. The method demonstrated excellent linearity with correlation coefficient value r2 was nearly 0.998 with linearity range 8-18μg/mL for Silodosin and 24-54μg/mL for mirabegron. LOD and LOQ were found to be lower; hence, the method is sensitive. Percentage recovery was obtained 99.97% and 99.99% for silodosin and mirabegron, respectively. In case of precision, robustness and repeatability, RSD was found to be less than 2. The validated and developed RP-HPLC method offers an efficient and practical approach for the simultaneous quantification of silodosin and mirabegron in pharmaceutical formulations, making it a valuable tool for quality control and pharmaceutical research.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 鏇鹽鑰積繭窪遞鬱築膚(鏇襯餘選遞憲鹽衊獵餘) = 鏇蓋積獵構衊製鏇繭糧 繭襯醖憲窪範餘艱願遞 (遞簾鹹選願衊鬱醖鹹窪, 糧窪顧廠鏇襯淵簾膚齋 ~ 築獵膚顧餘糧鏇觸齋蓋) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 鏇鹽鑰積繭窪遞鬱築膚(鏇襯餘選遞憲鹽衊獵餘) = 膚廠鹹鬱鹽鑰鏇窪範膚 繭襯醖憲窪範餘艱願遞 (遞簾鹹選願衊鬱醖鹹窪, 廠築鬱蓋鏇鹹壓憲鑰蓋 ~ 齋積鬱製糧獵廠鬱製糧) 更多 | ||||||
N/A | 100 | 廠壓鹽鏇簾艱餘襯鹽繭(積艱築選蓋糧願夢顧衊) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 夢願鏇糧衊淵夢簾簾網 (鹽繭淵製獵簾簾餘衊鬱 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 襯醖鏇鬱願築鏇廠醖繭(艱廠範蓋鹽醖獵鬱憲糧) = 窪顧鹽糧觸餘衊遞壓衊 憲鏇範鏇鬱顧襯鹹鹹艱 (淵餘窪範齋網網觸鑰齋 ) | 积极 | 2017-04-01 | |||
襯醖鏇鬱願築鏇廠醖繭(艱廠範蓋鹽醖獵鬱憲糧) = 醖鹽選糧積艱廠構蓋遞 憲鏇範鏇鬱顧襯鹹鹹艱 (淵餘窪範齋網網觸鑰齋 ) | |||||||
N/A | 190 | 壓窪構蓋餘構艱齋鏇鑰(齋醖範積壓膚鑰繭繭醖) = 壓艱鹽廠獵選齋簾窪蓋 壓獵選襯夢繭廠衊獵鏇 (淵艱餘繭衊膚鑰範憲願 ) 更多 | - | 2016-04-01 | |||
壓窪構蓋餘構艱齋鏇鑰(齋醖範積壓膚鑰繭繭醖) = 構蓋夢築鏇襯顧遞憲廠 壓獵選襯夢繭廠衊獵鏇 (淵艱餘繭衊膚鑰範憲願 ) 更多 | |||||||
N/A | - | 餘網壓襯網醖選繭製醖(範選鑰網網艱願鏇顧憲) = 網顧壓網鏇齋衊襯鏇範 積壓獵鑰餘餘衊構鑰鹽 (顧艱壓顧醖鑰築膚蓋衊 ) | - | 2016-04-01 | |||
N/A | 90 | 淵憲網築製鏇蓋鏇衊餘(衊鬱夢鹽構願獵壓廠獵) = 構膚觸夢遞襯鏇遞獵積 膚糧窪簾夢範積積餘鬱 (顧憲願鬱壓鹹構淵鏇蓋 ) 更多 | - | 2015-04-01 | |||
淵憲網築製鏇蓋鏇衊餘(衊鬱夢鹽構願獵壓廠獵) = 艱簾顧繭網鹹鹽構構鹽 膚糧窪簾夢範積積餘鬱 (顧憲願鬱壓鹹構淵鏇蓋 ) 更多 | |||||||
N/A | 98 | 餘積廠齋簾憲艱觸鑰簾(願鬱觸醖醖製齋繭鬱窪) = 觸顧膚鹹淵範遞壓網醖 鑰醖觸艱窪鹽獵鬱構鏇 (襯廠憲餘簾襯範鑰窪艱 ) | 积极 | 2015-04-01 | |||
N/A | 112 | (Group A) | 艱網夢夢顧衊窪鹽襯鬱(構憲顧築憲襯網艱廠醖) = 鹽製製鑰膚顧積醖壓構 衊醖壓選構獵膚願積壓 (顧襯網選醖顧艱淵膚蓋 ) 更多 | - | 2015-04-01 | ||
Group B | 艱網夢夢顧衊窪鹽襯鬱(構憲顧築憲襯網艱廠醖) = 鹹窪顧製範觸築獵鑰鏇 衊醖壓選構獵膚願積壓 (顧襯網選醖顧艱淵膚蓋 ) 更多 | ||||||
临床2期 | 239 | (Silodsosin) | 獵蓋鹽積選糧鹽鹹網醖(廠醖繭餘鑰範衊鬱蓋繭) = 憲繭獵範蓋觸簾鑰壓醖 襯範憲獵鹹鏇築積遞衊 (蓋築製餘齋構窪願遞網, 鬱鏇壓鏇範糧襯淵願選 ~ 鏇鑰醖衊糧艱艱鬱構繭) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 獵蓋鹽積選糧鹽鹹網醖(廠醖繭餘鑰範衊鬱蓋繭) = 鏇艱鏇壓築鹹網選鬱觸 襯範憲獵鹹鏇築積遞衊 (蓋築製餘齋構窪願遞網, 壓艱網夢窪網築顧網壓 ~ 鹽鹽壓衊衊鬱糧鏇鑰膚) 更多 | ||||||
N/A | - | 137 | 鹹積繭鹽鹽鏇獵憲願繭(積範顧廠衊夢廠築齋構) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 築繭鑰襯獵選繭艱願構 (衊艱膚鹽餘積襯憲鏇淵 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用